JP2024537797A5 - - Google Patents

Info

Publication number
JP2024537797A5
JP2024537797A5 JP2024519554A JP2024519554A JP2024537797A5 JP 2024537797 A5 JP2024537797 A5 JP 2024537797A5 JP 2024519554 A JP2024519554 A JP 2024519554A JP 2024519554 A JP2024519554 A JP 2024519554A JP 2024537797 A5 JP2024537797 A5 JP 2024537797A5
Authority
JP
Japan
Prior art keywords
sequence
nucleic acid
acid molecule
nucleotide sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024519554A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024537797A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/077228 external-priority patent/WO2023056331A1/en
Publication of JP2024537797A publication Critical patent/JP2024537797A/ja
Publication of JP2024537797A5 publication Critical patent/JP2024537797A5/ja
Pending legal-status Critical Current

Links

JP2024519554A 2021-09-30 2022-09-29 低下した免疫原性を有する第viii因子ポリペプチドをコードする核酸 Pending JP2024537797A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163250575P 2021-09-30 2021-09-30
US63/250,575 2021-09-30
PCT/US2022/077228 WO2023056331A1 (en) 2021-09-30 2022-09-29 Nucleic acids encoding factor viii polypeptides with reduced immunogenicity

Publications (2)

Publication Number Publication Date
JP2024537797A JP2024537797A (ja) 2024-10-16
JP2024537797A5 true JP2024537797A5 (https=) 2025-10-06

Family

ID=83996337

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024519554A Pending JP2024537797A (ja) 2021-09-30 2022-09-29 低下した免疫原性を有する第viii因子ポリペプチドをコードする核酸

Country Status (11)

Country Link
US (1) US20240350672A1 (https=)
EP (1) EP4408874A1 (https=)
JP (1) JP2024537797A (https=)
KR (1) KR20240067122A (https=)
CN (1) CN118019758A (https=)
AU (1) AU2022355088A1 (https=)
CA (1) CA3232988A1 (https=)
IL (1) IL311725A (https=)
MX (1) MX2024003963A (https=)
TW (1) TW202346327A (https=)
WO (1) WO2023056331A1 (https=)

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
ES8801674A1 (es) 1985-04-12 1988-02-16 Genetics Inst Un procedimiento para la preparacion de una proteina que presenta actividad procoagulante.
KR910006424B1 (ko) 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
DE3785102T2 (de) 1986-01-03 1993-07-22 Genetics Inst Verfahren zur herstellung von faktor-viii:c-typ-proteinen.
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5543502A (en) 1986-06-24 1996-08-06 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
US6060447A (en) 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
IL86693A (en) 1987-06-12 1994-06-24 Stichting Centraal Lab Proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
ATE236987T1 (de) 1992-11-13 2003-04-15 Idec Pharma Corp Konsensus-kozak-sequenzen zur säugetier- exprimierung
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
GB9621680D0 (en) 1996-10-17 1996-12-11 Oxford Biomedica Ltd Lentiviral vectors
PT904392E (pt) 1996-10-17 2001-06-29 Oxford Biomedica Ltd Vectores retrovirais
GB9622500D0 (en) 1996-10-29 1997-01-08 Oxford Biomedica Ltd Therapeutic gene
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
AU737155B2 (en) 1997-03-14 2001-08-09 Biogen Idec Inc. Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
US6207455B1 (en) 1997-05-01 2001-03-27 Lung-Ji Chang Lentiviral vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6615782B1 (en) 2002-04-12 2003-09-09 Delphi Technologies, Inc. Two-step finger follower rocker arm
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
ES2298745T3 (es) 2003-04-24 2008-05-16 Fondazione Centro San Raffaele Del Monte Tabor Promotores bidireccionales de sintesis y utilizacion de los mismos.
CA2609142C (en) 2005-05-27 2016-02-09 Fondazione Centro San Raffaele Del Monte Tabor Therapeutic gene vectors comprising mirna target sequences
EP2364362B1 (en) 2008-11-12 2015-10-21 Ospedale San Raffaele S.r.l. Gene vector for inducing transgene-specific immune tolerance
ES2610356T3 (es) 2009-02-03 2017-04-27 Amunix Operating Inc. Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US9050269B2 (en) 2009-03-10 2015-06-09 The Trustees Of The University Of Pennsylvania Protection of virus particles from phagocytosis by expression of CD47
PL2424571T3 (pl) 2009-04-30 2020-10-19 Ospedale San Raffaele S.R.L Wektor genowy
KR101813727B1 (ko) 2009-06-08 2018-01-02 아뮤닉스 오퍼레이팅 인코포레이티드 성장 호르몬 폴리펩타이드 및 이를 제조하고 사용하는 방법
WO2010144508A1 (en) 2009-06-08 2010-12-16 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
CA2771999A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
WO2011028344A2 (en) 2009-08-25 2011-03-10 Amunix Operating Inc. Interleukin-1 receptor antagonist compositions and methods of making and using same
JP6256882B2 (ja) * 2012-02-15 2018-01-10 アムニクス オペレーティング インコーポレイテッド 第viii因子組成物、ならびに組成物の作製方法および用途
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
AU2015204646B2 (en) 2014-01-10 2020-08-27 Bioverativ Therapeutics Inc. Factor VIII chimeric proteins and uses thereof
TWI707951B (zh) 2015-04-08 2020-10-21 美商健臻公司 過大腺相關載體之製造
CA3012695A1 (en) * 2016-02-01 2017-08-10 Bioverativ Therapeutics Inc. Optimized factor viii genes
EP3833766A1 (en) * 2018-08-09 2021-06-16 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
KR20220097891A (ko) * 2019-09-30 2022-07-08 바이오버라티브 테라퓨틱스 인크. 렌티바이러스 벡터 제형

Similar Documents

Publication Publication Date Title
CN102741405B (zh) 提高基因表达的系统和保持有该系统的载体
AU2009240054B2 (en) Liver-specific nucleic acid regulatory elements and methods and use thereof
JP2024083479A5 (https=)
CN112040988A (zh) 修饰的aav衣壳多肽用于治疗肌肉疾病
JP2022517174A5 (https=)
FI4211231T3 (fi) Peptidimodifioitu aav-kapsidi
JP2023544683A5 (https=)
JP2004537260A5 (https=)
RU2017126975A (ru) Модифицированные посттранскрипционные регуляторные элементы вирусов гепатита
JP2022500066A5 (https=)
JP2021519791A5 (https=)
JP2020508685A5 (https=)
JP2018502583A5 (https=)
JP2024511163A5 (https=)
AU2015229227A1 (en) Genomic insulator elements and uses thereof
US11618780B2 (en) Composition and method for activating latent human immunodeficiency virus (HIV)
JP2024533316A5 (https=)
JP2022530095A5 (https=)
JP2024523394A5 (https=)
JP2018537089A5 (https=)
JP2025513066A5 (https=)
JP2024513907A5 (https=)
JP2024515827A5 (https=)
Hofacre et al. Efficient therapeutic protein expression using retroviral replicating vector with 2A peptide in cancer models
JP2024537797A5 (https=)